Clinical Trials Browser

Phase 2 × Triple Negative Breast Neoplasms × Immunotherapy × Clear all

NCT06691594 2025-02-20

Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT02539017 2016-08-10

The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer

Phase 2 Withdrawn

Triple Negative Breast Neoplasms